L
Linda Lowes
Researcher at Nationwide Children's Hospital
Publications - 136
Citations - 5268
Linda Lowes is an academic researcher from Nationwide Children's Hospital. The author has contributed to research in topics: Medicine & Duchenne muscular dystrophy. The author has an hindex of 26, co-authored 111 publications receiving 3828 citations. Previous affiliations of Linda Lowes include University of Rochester & Drexel University.
Papers
More filters
Journal ArticleDOI
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Jerry R. Mendell,Samiah Al-Zaidy,Richard Shell,W. Dave Arnold,Louise R. Rodino-Klapac,Thomas W. Prior,Linda Lowes,Lindsay N. Alfano,K. Berry,Kathleen Church,John T. Kissel,Sukumar Nagendran,James L’Italien,Douglas M. Sproule,Courtney Wells,Jessica A. Cardenas,Marjet D. Heitzer,Allan Arman Kaspar,Sarah Corcoran,Lyndsey Braun,Shibi Likhite,Carlos Henrique Miranda,Kathrin Meyer,K.D. Foust,Arthur H.M. Burghes,Brian K. Kaspar +25 more
TL;DR: In patients with SMA1, a single intravenous infusion of adenoviral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts.
Journal ArticleDOI
Eteplirsen for the treatment of Duchenne muscular dystrophy
Jerry R. Mendell,Louise R. Rodino-Klapac,Zarife Sahenk,Kandice Roush,Loren Bird,Linda Lowes,Lindsay N. Alfano,Ann Maria Gomez,Sarah Lewis,Janaiah Kota,Vinod Malik,Kim Shontz,Christopher M. Walker,Kevin M. Flanigan,Marco Corridore,John R. Kean,Hugh D. Allen,Chris Shilling,Kathleen R. Melia,Peter Sazani,Jay B. Saoud,Edward M. Kaye +21 more
TL;DR: The authors used a double-blind placebo controlled protocol to test eteplirsen's ability to induce dystrophin production and improve distance walked on the 6-minute walk test (6MWT).
Journal ArticleDOI
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
Jerry R. Mendell,Nathalie Goemans,Linda Lowes,Lindsay N. Alfano,K. Berry,James Shao,Edward M. Kaye,Eugenio Mercuri +7 more
TL;DR: In this article, the authors evaluated the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip exon 51 in patients with Duchenne muscular dystrophy.
Journal ArticleDOI
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald,Craig Campbell,Ricardo Erazo Torricelli,Richard S. Finkel,Richard S. Finkel,Kevin M. Flanigan,Nathalie Goemans,Peter Heydemann,Anna Kamińska,Janbernd Kirschner,Francesco Muntoni,Andrés Nascimento Osorio,Ulrike Schara,Thomas Sejersen,Perry B. Shieh,H. Lee Sweeney,Haluk Topaloglu,Mar Tulinius,Juan J. Vílchez,Thomas Voit,Thomas Voit,Brenda Wong,Gary Elfring,H. Kroger,Xiaohui Luo,Joseph McIntosh,Tuyen Ong,Peter Riebling,Marcio Souza,R. Spiegel,Stuart W. Peltz,Eugenio Mercuri,Lindsay N. Alfano,Michelle Eagle,M. James,Linda Lowes,Anna Mayhew,Elena S. Mazzone,Leslie Nelson,Kristy Rose,Hoda Abdel-Hamid,Susan D. Apkon,Richard J. Barohn,Enrico Bertini,Clemens Bloetzer,Lausanne Canton de Vaud,Russell J. Butterfield,Brigitte Chabrol,Jong-Hee Chae,Daehak-ro Jongno-gu,Giacomi Pietro Comi,Basil T. Darras,Jahannaz Dastgir,Isabelle Desguerre,Raul G Escobar,Erika Finanger,Michela Guglieri,Imelda Hughes,Susan T. Iannaccone,Kristi J. Jones,Peter I. Karachunski,Martin Kudr,Timothy Lotze,Jean K. Mah,Katherine D. Mathews,Yoram Nevo,Julie A. Parsons,Yann Péréon,Alexandra Prufer de Queiroz Campos Araujo,J. Ben Renfroe,Maria Bernadete Dutra de Resende,Monique M. Ryan,Kathryn Selby,Gihan Tennekoon,Giuseppe Vita +74 more
TL;DR: Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity, and there was a significant effect of ataluren in the prespecified subgroup of patients in the intention-to-treat population.
Journal ArticleDOI
A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Jerry R. Mendell,Jerry R. Mendell,Zarife Sahenk,Zarife Sahenk,Vinod Malik,A.M. Gomez,Kevin M. Flanigan,Kevin M. Flanigan,Linda Lowes,Lindsay N. Alfano,K. Berry,Eric Meadows,Sarah Lewis,Lyndsey Braun,Kim Shontz,Maria Rouhana,Kelly Reed Clark,Kelly Reed Clark,Xiomara Q. Rosales,Xiomara Q. Rosales,Samiah Al-Zaidy,Samiah Al-Zaidy,Alessandra Govoni,Louise R. Rodino-Klapac,Louise R. Rodino-Klapac,Mark J. Hogan,Brian K. Kaspar,Brian K. Kaspar +27 more
TL;DR: Benefit showing reduced endomysial fibrosis, reduced central nucleation, more normal fiber size distribution with muscle hypertrophy, especially at high dose is encouraging for treatment of dystrophin-deficient muscle diseases.